JP7401439B2 - 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ - Google Patents

心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ Download PDF

Info

Publication number
JP7401439B2
JP7401439B2 JP2020539814A JP2020539814A JP7401439B2 JP 7401439 B2 JP7401439 B2 JP 7401439B2 JP 2020539814 A JP2020539814 A JP 2020539814A JP 2020539814 A JP2020539814 A JP 2020539814A JP 7401439 B2 JP7401439 B2 JP 7401439B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
group
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020539814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511331A5 (enExample
JP2021511331A (ja
Inventor
チーユアン チュアン，
ブラッドリー ピー． モーガン，
マーク ヴァンダーウォル，
ウェンユエ ワン，
ルーク ダブリュー． アシュクラフト，
Original Assignee
サイトキネティックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65324663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7401439(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サイトキネティックス， インコーポレイテッド filed Critical サイトキネティックス， インコーポレイテッド
Publication of JP2021511331A publication Critical patent/JP2021511331A/ja
Publication of JP2021511331A5 publication Critical patent/JP2021511331A5/ja
Priority to JP2023163639A priority Critical patent/JP2023169374A/ja
Application granted granted Critical
Publication of JP7401439B2 publication Critical patent/JP7401439B2/ja
Priority to JP2025065043A priority patent/JP2025106500A/ja
Priority to JP2026061251A priority patent/JP2026113610A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020539814A 2018-01-19 2019-01-18 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ Active JP7401439B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023163639A JP2023169374A (ja) 2018-01-19 2023-09-26 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ
JP2025065043A JP2025106500A (ja) 2018-01-19 2025-04-10 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ
JP2026061251A JP2026113610A (ja) 2018-01-19 2026-04-02 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862619643P 2018-01-19 2018-01-19
US62/619,643 2018-01-19
US201862745724P 2018-10-15 2018-10-15
US62/745,724 2018-10-15
PCT/US2019/014344 WO2019144041A1 (en) 2018-01-19 2019-01-18 Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023163639A Division JP2023169374A (ja) 2018-01-19 2023-09-26 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ

Publications (3)

Publication Number Publication Date
JP2021511331A JP2021511331A (ja) 2021-05-06
JP2021511331A5 JP2021511331A5 (enExample) 2022-01-25
JP7401439B2 true JP7401439B2 (ja) 2023-12-19

Family

ID=65324663

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020539814A Active JP7401439B2 (ja) 2018-01-19 2019-01-18 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ
JP2023163639A Withdrawn JP2023169374A (ja) 2018-01-19 2023-09-26 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ
JP2025065043A Withdrawn JP2025106500A (ja) 2018-01-19 2025-04-10 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ
JP2026061251A Pending JP2026113610A (ja) 2018-01-19 2026-04-02 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023163639A Withdrawn JP2023169374A (ja) 2018-01-19 2023-09-26 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ
JP2025065043A Withdrawn JP2025106500A (ja) 2018-01-19 2025-04-10 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ
JP2026061251A Pending JP2026113610A (ja) 2018-01-19 2026-04-02 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ

Country Status (32)

Country Link
US (4) US10836755B2 (enExample)
EP (2) EP3740481B9 (enExample)
JP (4) JP7401439B2 (enExample)
KR (1) KR102797441B1 (enExample)
CN (3) CN111757875B (enExample)
AU (2) AU2019208331C1 (enExample)
BR (1) BR112020014428A2 (enExample)
CA (2) CA3087283C (enExample)
CL (2) CL2020001871A1 (enExample)
CO (1) CO2020009225A2 (enExample)
DK (1) DK3740481T5 (enExample)
EC (1) ECSP20044709A (enExample)
ES (1) ES2986630T3 (enExample)
FI (2) FI3740481T3 (enExample)
HR (1) HRP20241014T2 (enExample)
HU (1) HUE067913T2 (enExample)
IL (1) IL276094B2 (enExample)
LT (2) LT3740481T (enExample)
MA (1) MA51620B1 (enExample)
MD (1) MD3740481T3 (enExample)
MX (2) MX2020007532A (enExample)
MY (1) MY203855A (enExample)
PH (1) PH12020551090A1 (enExample)
PL (1) PL3740481T3 (enExample)
PT (1) PT3740481T (enExample)
RS (1) RS66042B9 (enExample)
SG (1) SG11202006296YA (enExample)
SI (1) SI3740481T1 (enExample)
SM (1) SMT202400329T1 (enExample)
TW (2) TWI835770B (enExample)
UY (1) UY38057A (enExample)
WO (1) WO2019144041A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022542803A (ja) * 2019-07-17 2022-10-07 サイトキネティックス， インコーポレイテッド （ｒ）－ｎ－（５－（５－イソプロピル－１，２，４－オキサジアゾール－３－イル）－２，３－ジヒドロ－１ｈ－インデン－１－イル）－２－メチル－２ｈ－テトラゾール－５－カルボキサミドの多形

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
EP3814343B1 (en) * 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7438148B2 (ja) * 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
EP4446314A3 (en) * 2019-05-03 2025-03-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
LT3999180T (lt) * 2019-07-17 2024-08-26 Cytokinetics, Inc. (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h-pirazol-4-karboksamido polimorfai
WO2021011808A1 (en) * 2019-07-17 2021-01-21 Cytokinetics, Inc. Cardiac sarcomere inhibitor oral formulations
KR20230079053A (ko) 2020-08-28 2023-06-05 미요카디아, 인크. 미오신 조절제를 이용한 치료 방법
CN112094253B (zh) * 2020-09-10 2023-01-10 株式会社大熊制药 用于制备sglt抑制剂中间体的合成方法
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
JP2024530111A (ja) 2021-08-03 2024-08-16 サイトキネティックス， インコーポレイテッド アフィカムテンを調製するための工程
CN119789856A (zh) 2022-04-26 2025-04-08 迈奥卡迪亚公司 施用肌球蛋白抑制剂的方法
US20240091203A1 (en) * 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
JP2025525913A (ja) 2022-08-04 2025-08-07 サイトキネティックス， インコーポレイテッド 閉塞性肥大型心筋症を治療するための方法
JP2025527504A (ja) 2022-08-18 2025-08-22 サイトキネティックス， インコーポレイテッド 骨格筋速筋型ミオシン阻害剤としてのインダン誘導体及びクマラン誘導体
WO2024134498A1 (en) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Solid state forms of aficamten and process for preparation thereof
CN115894361A (zh) * 2022-12-28 2023-04-04 上海合全药业股份有限公司 一种钯催化合成1-乙酰基-6-氰基-四氢喹啉的方法
CN120712262A (zh) * 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
CN122070481A (zh) 2023-11-01 2026-05-19 百时美施贵宝公司 基于蛋白质水平用肌球蛋白抑制剂进行治疗的方法
WO2025175141A1 (en) * 2024-02-16 2025-08-21 Cytokinetics, Incorporated Fast skeletal muscle myosin inhibitors
WO2025198687A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases
CN122301864A (zh) * 2024-12-31 2026-06-30 广东东阳光药业股份有限公司 取代的茚类化合物及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515884A (ja) 2003-01-14 2006-06-08 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
JP2007516176A (ja) 2003-06-20 2007-06-21 アムジエン・インコーポレーテツド ピペラジン誘導体及び使用方法
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
JP2008503467A (ja) 2004-06-17 2008-02-07 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
JP2008526761A (ja) 2004-12-31 2008-07-24 アラントス ファーマシューティカルズ インコーポレイテッド 多環式ビス−アミドｍｍｐ阻害剤
WO2010033701A2 (en) 2008-09-19 2010-03-25 Genzyme Corporation Inhibitors of sphingosine kinase 1
JP2014511359A (ja) 2011-01-24 2014-05-15 エフ．ホフマン−ラ ロシュ アーゲー 新しいアリール−ベンゾシクロアルキルアミド誘導体

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633499A (en) 1899-06-29 1899-09-19 Oil Well Supply Co Coupling for pipes, tubes, or casings.
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US5919785A (en) 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2470427C (en) 2001-12-21 2012-07-10 Cytokinetics, Incorporated Compositions and methods for treating heart failure
US20030158186A1 (en) 2001-12-21 2003-08-21 Fady Malik Compositions and methods for treating heart failure
WO2004000764A2 (en) * 2002-06-24 2003-12-31 Vivoquest, Inc. BENZO(b)FURAN DIMERS
JP2006516288A (ja) 2003-01-21 2006-06-29 アーケミックス コーポレイション 眼の薬物療法において有用なアプタマー治療薬
WO2004086865A1 (en) 2003-03-27 2004-10-14 Cytokinetics, Inc. Compounds, compositions and methods
CN101137414A (zh) * 2004-12-31 2008-03-05 欧兰拓制药股份有限公司 多环双酰胺mmp抑制剂
TW200718692A (en) 2005-04-22 2007-05-16 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
JP5463034B2 (ja) * 2005-05-20 2014-04-09 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド ピリミジン若しくはトリアジン縮合二環式メタロプロテアーゼ阻害薬
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
SA08290245B1 (ar) 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
US20090192168A1 (en) 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
ES2459468T3 (es) 2009-05-15 2014-05-09 Novartis Ag Arilpiridinas como inhibidores de aldosterona sintasa
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
WO2013048928A1 (en) * 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
TWI576347B (zh) 2012-01-20 2017-04-01 艾克泰聯製藥有限公司 作為ｐ２ｘ受體拮抗劑之雜環醯胺衍生物
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
WO2015142001A2 (ko) 2014-03-21 2015-09-24 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
US9663516B2 (en) 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
JP2018502137A (ja) * 2015-01-20 2018-01-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 第ＸＩａ因子阻害剤
SG11201705928XA (en) 2015-01-22 2017-08-30 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
CN105884752B (zh) * 2015-02-13 2018-08-31 山东轩竹医药科技有限公司 并环类回旋酶和拓扑异构酶iv抑制剂
US10501425B2 (en) 2015-10-02 2019-12-10 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
CN108430997B (zh) 2015-12-17 2021-06-04 先正达参股股份有限公司 杀微生物的噁二唑衍生物
US20190364899A1 (en) 2015-12-18 2019-12-05 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
CA3022432A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Sigma receptor binders
EP3475275B1 (en) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
SI3519416T1 (sl) 2016-09-27 2021-08-31 Merck Sharp & Dohme Corp. Derivati kromana, izokromana in dihidroizobenzofurana kot mGluR2-negativni alosterični modulatorji, sestavki in njihova uporaba
WO2018089433A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
JP2020023442A (ja) 2016-12-19 2020-02-13 住友化学株式会社 オキサジアゾール化合物及び植物病害防除方法
US20200000822A1 (en) 2017-02-23 2020-01-02 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
CN110325517B (zh) 2017-02-28 2021-03-02 南京明德新药研发有限公司 螺环类化合物及其应用
IL322175A (en) 2017-08-04 2025-09-01 Myokardia Inc Treatment of hypertrophic cardiomyopathy (HCM) with pyrimidinedione compounds
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
US10981905B2 (en) 2018-08-31 2021-04-20 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
LT3999180T (lt) 2019-07-17 2024-08-26 Cytokinetics, Inc. (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h-pirazol-4-karboksamido polimorfai
WO2021011808A1 (en) 2019-07-17 2021-01-21 Cytokinetics, Inc. Cardiac sarcomere inhibitor oral formulations
KR20230079053A (ko) 2020-08-28 2023-06-05 미요카디아, 인크. 미오신 조절제를 이용한 치료 방법
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
JP2024530111A (ja) 2021-08-03 2024-08-16 サイトキネティックス， インコーポレイテッド アフィカムテンを調製するための工程
CN119789856A (zh) 2022-04-26 2025-04-08 迈奥卡迪亚公司 施用肌球蛋白抑制剂的方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515884A (ja) 2003-01-14 2006-06-08 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
JP2007516176A (ja) 2003-06-20 2007-06-21 アムジエン・インコーポレーテツド ピペラジン誘導体及び使用方法
JP2008503467A (ja) 2004-06-17 2008-02-07 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
JP2008526761A (ja) 2004-12-31 2008-07-24 アラントス ファーマシューティカルズ インコーポレイテッド 多環式ビス−アミドｍｍｐ阻害剤
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2010033701A2 (en) 2008-09-19 2010-03-25 Genzyme Corporation Inhibitors of sphingosine kinase 1
JP2014511359A (ja) 2011-01-24 2014-05-15 エフ．ホフマン−ラ ロシュ アーゲー 新しいアリール−ベンゾシクロアルキルアミド誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Pam R Taub et al.，Perturbations in skeletal muscle sarcomere structure in patients with heart failure and Type2 diabetes: restorative effects of (-)-epicatechin-rich cocoa.，Clinical Science，2013年，125巻，383-389頁
Rene Martin et al.，Total Synthesis of Pentabromo- and Pentachloropseudilin, and Synthetic Analogues - Allosteric Inhibitors of Myosin ATPase，Angewandte，2009年，8042-8046頁

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022542803A (ja) * 2019-07-17 2022-10-07 サイトキネティックス， インコーポレイテッド （ｒ）－ｎ－（５－（５－イソプロピル－１，２，４－オキサジアゾール－３－イル）－２，３－ジヒドロ－１ｈ－インデン－１－イル）－２－メチル－２ｈ－テトラゾール－５－カルボキサミドの多形

Also Published As

Publication number Publication date
CN117964573B (zh) 2026-04-14
JP2025106500A (ja) 2025-07-15
TW202608872A (zh) 2026-03-01
ES2986630T3 (es) 2024-11-12
SMT202400329T1 (it) 2024-09-16
CO2020009225A2 (es) 2020-08-10
JP2023169374A (ja) 2023-11-29
EP4491622A3 (en) 2025-04-30
US20190256504A1 (en) 2019-08-22
CA3087283C (en) 2026-01-27
SI3740481T1 (sl) 2024-09-30
CL2022001091A1 (es) 2023-01-20
EP3740481B9 (en) 2024-10-23
NZ765795A (en) 2026-01-30
EP3740481B1 (en) 2024-06-26
CA3087283A1 (en) 2019-07-25
MX2022014312A (es) 2022-12-07
US20210147399A1 (en) 2021-05-20
AU2024204859A1 (en) 2024-08-01
DK3740481T3 (da) 2024-07-08
FIC20265017I1 (fi) 2026-07-10
SG11202006296YA (en) 2020-08-28
AU2019208331C1 (en) 2024-11-14
US11472796B2 (en) 2022-10-18
DK3740481T5 (da) 2025-05-05
UY38057A (es) 2019-08-30
TW201940471A (zh) 2019-10-16
HRP20241014T2 (hr) 2025-05-23
IL276094A (en) 2020-08-31
EP3740481A1 (en) 2020-11-25
MA51620B1 (fr) 2024-10-31
PH12020551090A1 (en) 2021-09-01
CA3252332A1 (en) 2025-06-04
HRP20241014T1 (hr) 2024-11-08
CN111757875B (zh) 2024-01-09
CN111757875A (zh) 2020-10-09
CL2020001871A1 (es) 2020-10-23
KR102797441B1 (ko) 2025-04-22
LTPA2026525I1 (enExample) 2026-08-10
AU2019208331B2 (en) 2024-05-02
EP4491622A2 (en) 2025-01-15
IL276094B1 (en) 2023-04-01
WO2019144041A1 (en) 2019-07-25
CN117964573A (zh) 2024-05-03
MY203855A (en) 2024-07-22
US12065436B2 (en) 2024-08-20
FI3740481T3 (fi) 2024-07-30
KR20200112895A (ko) 2020-10-05
RS66042B9 (sr) 2025-05-30
JP2026113610A (ja) 2026-07-07
IL276094B2 (en) 2023-08-01
MA51620A (fr) 2020-11-25
TWI835770B (zh) 2024-03-21
US10836755B2 (en) 2020-11-17
RS66042B1 (sr) 2024-11-29
MD3740481T3 (ro) 2025-06-30
BR112020014428A2 (pt) 2020-12-01
AU2019208331A1 (en) 2020-07-16
US20250059173A1 (en) 2025-02-20
CN117924208A (zh) 2024-04-26
PL3740481T3 (pl) 2024-11-04
LT3740481T (lt) 2024-08-26
PT3740481T (pt) 2024-09-13
HUE067913T2 (hu) 2024-11-28
JP2021511331A (ja) 2021-05-06
ECSP20044709A (es) 2020-10-30
MX2020007532A (es) 2020-09-09
TWI898447B (zh) 2025-09-21
US20230119665A1 (en) 2023-04-20
FI3740481T9 (fi) 2025-05-07
MD3740481T2 (ro) 2024-12-31
TW202436291A (zh) 2024-09-16

Similar Documents

Publication Publication Date Title
JP2023169374A (ja) 心筋節阻害剤としてのジヒドロベンゾフランおよびインデンアナログ
JP7610985B2 (ja) 心臓サルコメア阻害剤
JP7825650B2 (ja) 心筋サルコメア阻害剤
JP7438148B2 (ja) 心臓サルコメア阻害剤
HK40110776A (en) Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
HK40106567A (en) Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
HK40039882A (en) Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
HK40039882B (en) Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
EA043133B1 (ru) Аналоги дигидробензофурана и индена в качестве ингибиторов саркомера сердца

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231207

R150 Certificate of patent or registration of utility model

Ref document number: 7401439

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150